Board Changes at Novogen Limited Announced
23 mars 2009 10h46 HE
|
Novogen, Limited
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - March 23, 2009) - Novogen Limited (ASX: NRT) (NASDAQ: NVGN) is pleased to announce the appointment of Mr. William
D. Rueckert to its Board of...
Novogen's NV-128, a Novel mTOR Inhibitor, Shows Potential Activity Against Cancer Stem Cells
01 déc. 2008 08h10 HE
|
NOVOGEN LIMITED
SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - December 1, 2008) - Pharmaceutical company
Novogen Limited (NASDAQ: NVGN) (ASX: NRT) today announced that work
performed in collaboration with a...
Marshall Edwards' Phenoxodiol and Novogen's NV-128 Display Divergent Mechanisms of Action but Potent Synergistic Anti-Cancer Activity When Used in Combination
30 oct. 2008 19h19 HE
|
Novogen, Limited
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - October 30, 2008) - Pre-clinical studies
presented at the 9th International Conference on Membrane Redox Systems in
Wellington New Zealand this...
Novogen Signs Spanish Patent License With Laboratorios Casen-Fleet
23 juin 2008 08h00 HE
|
Novogen, Limited
STAMFORD, CT and SYDNEY, AUSTRALIA--(Marketwire - June 23, 2008) - Novogen Limited (ASX: NRT) (NASDAQ: NVGN), the registered owner of the European Patent "Use of
isoflavone phyto-oestrogen extracts...
Novogen's NV-128 Is a Unique Inhibitor of mTOR Dephosphorylation Leading to Caspase Independent Death in Chemoresistant Cancer Cells
15 avr. 2008 17h25 HE
|
Novogen, Limited
SAN DIEGO, CA--(Marketwire - April 15, 2008) - Pre-clinical studies reviewed during an oral
presentation here today at the annual meeting of the American Association
for Cancer Research demonstrate...
Novogen Cardiovascular Drug Enters Phase I Clinical Trial
02 avr. 2008 08h00 HE
|
Novogen, Limited
SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - April 2, 2008) - Novogen today
announced the commencement of a Phase I human clinical trial of the novel
cardiovascular drug, NV-27. This drug is...
Glycotex, Inc. Obtains Active IND From US Food and Drug Administration for GLYC-101 Wound Healing Compound
07 janv. 2008 18h58 HE
|
Glycotex, Inc., Novogen Limited
ROCKVILLE, MD--(Marketwire - January 7, 2008) - Glycotex, Inc. announced today that it had
obtained an active Investigational New Drug Application (IND) from the US
Food and Drug Administration (FDA)...
Novogen's Investigational Drug for Inflammatory Bowel Disease Has Positive Results Following Phase Ib Trial
04 déc. 2007 08h01 HE
|
Novogen, Limited
STAMFORD, CT and SYDNEY, AUSTRALIA--(Marketwire - December 4, 2007) - A recently completed
Phase Ib clinical trial of a new drug to treat inflammatory bowel disease
(IBD) indicates that treatment may...
Research Indicates Synthetic Compound NV-52 May Be Useful in Treatment of Inflammatory Bowel Disease
13 nov. 2007 08h04 HE
|
Novogen, Limited
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - November 13, 2007) - An article published
in a recent edition of the peer review journal Expert Opinion, Vol. 16, No.
8, reveals the compound...
Novogen Announces Collaboration Agreement to Bring Cosmetic Products to Market
25 oct. 2007 20h00 HE
|
Novogen
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - October 25, 2007) - Novogen Limited
(NASDAQ: NVGN) announced today a collaboration agreement to develop new
cosmetic applications. The finished...